Patents Assigned to Universitaet Zuerich
  • Patent number: 11680085
    Abstract: The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: June 20, 2023
    Assignees: VIROMETIX AG, UNIVERSITÄT ZÜRICH
    Inventors: Arin Ghasparian, Armando Zuniga, Aniebrys Marrero Nodarse, Oliver Rassek, John A. Robinson, Kerstin Möhle
  • Patent number: 11661676
    Abstract: The invention relates to a method for selecting a sequence set from a library of expressed nucleic acid sequences, wherein cells are provided, each cell comprises an expressed nucleic acid sequence expressed as a target protein. The cells are encapsulated by treating them with a cationic polysaccharide and subsequently treating them with an anionic polysaccharide, yielding encapsulated cells, perforating the membrane of the encapsulated cells, yielding solubilized compartments, contacting them with a ligand to said target protein, the ligand bearing a detectable label, and selecting a subset of solubilized compartments as a function of detectable label and isolating the expressed nucleic acid sequences from the selection as a selected sequence set.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: May 30, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Daniel Scott, Andreas Plückthun
  • Publication number: 20230151118
    Abstract: The present invention relates to a non-agonist ligand of ARTC1, which inhibits the ADP-ribosyltransferase activity of ARTC1, or an inhibitor nucleic acid sequence capable of downregulating or inhibiting expression of a target nucleic acid sequence encoding ARTC1, for use in prevention or treatment of cancer. The invention also relates to a method for diagnosis of cancer.
    Type: Application
    Filed: April 6, 2021
    Publication date: May 18, 2023
    Applicants: UNIVERSITÄT ZÜRICH, UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
    Inventors: Friedrich NOLTE, Stephan MENZEL, Tobias SUTER, Michael HOTTIGER, Denise DORVIGNIT-PEDROSO, Jesus GLAUS-GARZON, Kathrin NOWAK, Fabio AIMI
  • Publication number: 20230139165
    Abstract: The present invention relates to an immersion microscope objective (10) for inspecting a sample (S) in an immersion medium (M), comprising: at least one concave minor (3), at least one optical element (1) comprising an aspherical surface (2) facing the at least one concave minor (3), and an internal space (4) arranged between the at least one concave minor (3) and said aspherical surface (2), said internal space (4) being configured to be filled with an immersion medium (M) such that the immersion medium (M) contacts the at least one concave minor (3) and the aspherical surface (2). According to the present invention, the aspherical interface (2) is shaped such that the working distance (7) of the immersion microscope objective (10) varies by less than 1% when the refractive index n of said immersion medium (M) is increased or decreased by at least 0.025.
    Type: Application
    Filed: April 12, 2021
    Publication date: May 4, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Fabian Friedrich VOIGT, Fritjof HELMCHEN
  • Publication number: 20230116496
    Abstract: A modular artificial neural sensing system includes a hierarchical network of neural sensing units including a neuromimetic sensor array of artificial sensory synapses and sensory neurons for receiving physicochemical sensed signals and for outputting sensor output signals. An artificial neural network processor is adapted for processing the sensor output signals and includes processor neurons interconnected by processor synapses forming first connections and second connections. The processor outputs processor output signals. A first sensor interface feeds processed or unprocessed sensed signals into the processor. A second sensor interface receives output predicted signals from other neural sensing units and feeds processed or unprocessed output predicted signals into the processor. A signal decoder decodes the processor output signals and outputs decoder output signals.
    Type: Application
    Filed: January 21, 2021
    Publication date: April 13, 2023
    Applicants: UNIVERSITÄT ZÜRICH, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Josep Maria MARGARIT TAULÉ, Shih-Chii LIU, Cecilia JIMÉNEZ JORQUERA
  • Publication number: 20230107228
    Abstract: A computer-implemented method is used to adapt a first artificial neural network for data classification tasks. The first artificial neural network is characterized by a first number of first weight parameters, and includes a set of first network layers. The method includes freezing at least some of the first weight parameters of the first neural network to obtain frozen first weight parameters and duplicating the frozen first weight parameters to obtain duplicated first weight parameters. A second artificial neural network is applied to the duplicated first weight parameters to obtain modulated first weight parameters. The second artificial neural network is characterized by a second number of second weight parameters, the second number being smaller than the first number. The frozen first weight parameters are replaced in the first neural network with the modulated first weight parameters to obtain a modulated first artificial neural network adapted for a data classification task.
    Type: Application
    Filed: October 5, 2022
    Publication date: April 6, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Yuhuang HU, Shih-Chii LIU
  • Publication number: 20230106313
    Abstract: The invention provides a bacterial composition comprising, or consisting of, one or more of the genera of bacteria selected from Anaerostipes, and/or Roseburia, for treatment, or for prevention of recurrence, of cancer. In another aspect, the invention relates to a combination medicament for use in the treatment or the prevention of recurrence of cancer comprising a bacterial composition as specified herein and an antineoplastic treatment, particularly a combination medicament comprising a bacterial composition and a cancer chemotherapy drug, or a bacterial composition as provided herein and a cancer immunotherapy drug.
    Type: Application
    Filed: February 11, 2021
    Publication date: April 6, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Michael SCHARL, Ana MONTALBAN-ARQUES, Lubor BORSIG
  • Publication number: 20230045790
    Abstract: A sensor transformation attention network (STAN) model including sensors configured to collect input signals, attention modules configured to calculate attention scores of feature vectors corresponding to the input signals, a merge module configured to calculate attention values of the attention scores, and generate a merged transformation vector based on the attention values and the feature vectors, and a task-specific module configured to classify the merged transformation vector is provided.
    Type: Application
    Filed: October 18, 2022
    Publication date: February 16, 2023
    Applicants: SAMSUNG ELECTRONICS CO., LTD., Universitaet Zuerich
    Inventors: Stefan BRAUN, Daniel Neil, Enea Ceolini, Jithendar Anumula, Shih-Chii Lui
  • Publication number: 20230043147
    Abstract: The invention is related to a device (1) for receiving a biological sample (3) wherein the device (1) comprises a plurality of wells (10) wherein each well (10) comprises an inner surface (14) facing a volume (60) for receiving a biological sample (3). The inner surface (14) comprises a top section (20) and a bottom section (30). The top section (20) and the bottom section (30) are connected via a circumferential step (40). The circumferential step (40) forms a stop for a tip of a pipette (70).
    Type: Application
    Filed: December 9, 2020
    Publication date: February 9, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Karthiga Santhana KUMAR, Michael GROTZER, Martin BAUMGARTNER
  • Patent number: 11571474
    Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: February 7, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Martin Bachmann, Gary Jennings, Thomas Kündig, Gabriela Senti, Franziska Zabel
  • Publication number: 20230016003
    Abstract: The invention relates to a method to indicate the clinical outcome of a cancer patient by labelling a cancer sample with labelled molecular probes, assaying the expression of a plurality of biomolecules at the resolution of a single cell and assigning a cellular identity (CI) to each single cell in the sample based on their expression pattern; then assigning a single cell pathology (SCP) patient group according to the proportion of each CI the sample contains. The invention in other aspects relates to methods of treatment of a patient with anticancer drugs according to the patient's assignment to particular SCPs. Alternatively, this aspect may be formulated as the provision of certain drugs for treatment of cancer in patients characterized by tumours assigned to certain SCPs.
    Type: Application
    Filed: July 18, 2022
    Publication date: January 19, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Hartland JACKSON, Jana FISCHER, Bernd BODENMILLER
  • Patent number: 11517319
    Abstract: An occluder device is provided for occluding a cardiovascular defect or a gap between a medical device and adjacent body tissue, the device including a compliant balloon defining a fluid-tight balloon chamber and a balloon channel forming a longitudinal passage from a proximal to a distal side of the balloon, the balloon including a fluid port for filling a fluid into the balloon chamber. A tip and a base are coupled to the distal and the proximal sides of the balloon, respectively. At least one connecting strut is attached to the tip and to the base. An elongate actuator is disposed longitudinally slidable in the balloon channel and connected to the tip, and longitudinally slidable with respect to the base so as to set a distance between the tip and the base. A lock is configured to maintain the distance between the tip and the base. Other embodiments are also described.
    Type: Grant
    Filed: September 23, 2018
    Date of Patent: December 6, 2022
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Francesco Maisano, Andrea Guidotti, Idan Tobis, David Zarbatany
  • Publication number: 20220370079
    Abstract: An occlusion device (210) is provided for occluding a left atrial appendage (LAA), including a compliant balloon (230) defining a fluid-tight balloon chamber (232), and an actuating shaft (234), which is disposed at least partially within the balloon chamber (232) for setting a distance between distal and proximal end portions (236, 238) of the balloon (230). A proximal LAA-orifice cover (70) includes a frame (72) and a covering (74) fixed to the frame (72). An orifice-support stent (290) is fixed to and extends distally from the proximal LAA-orifice cover (70), and is generally cylindrical when in a radially-expanded state. Other embodiments are also described.
    Type: Application
    Filed: September 24, 2020
    Publication date: November 24, 2022
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Boaz HARARI, Andrea GUIDOTTI, Francesco MAISANO, Monica TOCCHI, Georgios STEFOPOULOS, Pietro GOZZOLI, Luca VICENTINI
  • Patent number: 11501154
    Abstract: A sensor transformation attention network (STAN) model including sensors, attention modules, a merge module and a task-specific module is provided. The attention modules calculate attention scores of feature vectors corresponding to the input signals collected by the sensors. The merge module calculates attention values of the attention scores, and generates a merged transformation vector based on the attention values and the feature vectors. The task-specific module classifies the merged transformation vector.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: November 15, 2022
    Assignees: SAMSUNG ELECTRONICS CO., LTD., UNIVERSITAET ZUERICH
    Inventors: Stefan Braun, Daniel Neil, Enea Ceolini, Jithendar Anumula, Shih-Chii Liu
  • Patent number: 11484321
    Abstract: An occluder device is provided for occluding a cardiovascular defect or a gap between a medical device and adjacent body tissue, the device including a compliant balloon defining a fluid-tight balloon chamber and a balloon channel forming a longitudinal passage from a proximal to a distal side of the balloon, the balloon including a fluid port for filling a fluid into the balloon chamber. A tip and a base are coupled to the distal and the proximal sides of the balloon, respectively. At least one connecting strut is attached to the tip and to the base. An elongate actuator is disposed longitudinally slidable in the balloon channel and connected to the tip, and longitudinally slidable with respect to the base so as to set a distance between the tip and the base. A lock is configured to maintain the distance between the tip and the base. Other embodiments are also described.
    Type: Grant
    Filed: September 23, 2018
    Date of Patent: November 1, 2022
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Francesco Maisano, Andrea Guidotti, Idan Tobis, David Zarbatany
  • Publication number: 20220315951
    Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
    Type: Application
    Filed: June 22, 2022
    Publication date: October 6, 2022
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
  • Publication number: 20220275432
    Abstract: The present invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis. The first nucleic acid comprises a first common sequence tract, a variable sequence tract and a second common sequence tract and the second nucleic acid comprises a first common sequence tract, optionally an variable sequence tract and a second common sequence tract. The first and the second nucleic acid sequence is contacted with a probe sequence that is reverse complementary to the first and second common sequence tract under conditions allowing the hybridization of the probe sequence to the first and second nucleic acid sequence, thereby forming a first probe hybrid and a second probe hybrid. Subsequently, the first and second probe hybrids are submitted to electrophoresis to detect the electrophoretic mobility of the first and second probe hybrid.
    Type: Application
    Filed: August 10, 2020
    Publication date: September 1, 2022
    Applicants: UNIVERSITÄT ZÜRICH, PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY
    Inventors: Hiroyuki KAKUI, Kentaro K. SHIMIZU, Misako YAMAZAKI
  • Patent number: 11421001
    Abstract: The template-fixed ?-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr, have CXCR4 antagonizing properties and can be used for where cancer is mediated or resulting from CXCR4 receptor activity.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 23, 2022
    Assignees: UNIVERSITAET ZUERICH, POLYPHOR LTD.
    Inventors: Daniel Obrecht, Frank Gombert, Steven J. Demarco, Christian Ludin, Jan Wim Vrijbloed, Kerstin Moehle, John-Anthony Robinson, Reshmi Mukherjee, Heiko Henze, Barbara Romagnoli
  • Patent number: 11401528
    Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: August 2, 2022
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
  • Patent number: 11395090
    Abstract: An illustrative method for estimating a direct-to-reverberant ratio of a sound signal is described, wherein the direct-to-reverberant ratio is indicative of a ratio between direct sound received from a sound source and reverberated sound received from reflections in an environment of the sound source. The method includes determining a first energy value of a sound signal for a first time frame; assigning to an onset value of the first time frame a positive value, if the difference of the first energy value of the first time frame and a second energy value of a preceding second time frame is greater than a threshold, and a zero value otherwise; and determining the direct-to-reverberant ratio by providing an onset signal comprising the onset value to a machine learning algorithm, which has been trained to determine the direct-to-reverberant ratio based on the onset signal.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: July 19, 2022
    Assignees: Universität Zürich, Sonova AG
    Inventor: Ruksana Giurda